Newsletter
| Promoter: | Hot Shot Stocks | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| MFTH | $5000 | 3917 |
| Max Profit: 15.38 % | Gain at close: 0.00 % |
|
Click here: Medisafe 1 Technologies Corp. MFTH.OBOVERVIEW
Protector device with locking mechanism ensures substance is only released from the hypodermic needle after positive technology-based pre-matching with the specific patient, using barcode technology. Direct annual cost of preventable drug related mortality & morbidity $177.4 billion. Annual potential addressable market in the US alone of $1.4 billion. MEDISAFE SOLUTION
Protector incorporating locking mechanism which ensures that medicinal substance cannot be released from the needle without positive pre-matching substance / specific patient.
TEAMThe current senior executives of Medisafe are:
 Jacob Elhadad - President & Director
from 1990 to 1994 Mr. Elhadad studied at the Talmudic Biblical Institution, Bet Hatalmud, Jerusalem, where he received BA in Biblical History, Science & Talmudic Studies. From 1994 until 1997 he continued his religious studies in the Ponavitz School of Talmudic Studies, Bnei Berak, where he received his Rabbinical Degree. In 1997 he commenced studies at Ramat Gan College in Business Management and Economics and from 1999 to 2001 served as a strategic consultant to the Israel Minister of the Interior. Since 2001 Mr. Elhadad has been Chief Executive Officer of Jelmm Trade Limited, an international diamond and jewelry, whilst continuing to serve part time as a strategic consultant to various members of the Israel Parliament. Yisrael Gottlieb – Secretary & Director
from 1999 until 2003 Mr. Gottlieb studied religious studies in the Gur Talmudic University in Haifa. Since 2004 he has been an independent consultant to various companies, assisting in patent designs and related product development and enhancements. Tali Skoczylas – M.D. Head of medical advisory board.
Specialist in Internal Medicine and Geriatrics, Involved in the clinical, administrative and business aspects of Healthcare and evidence-based Pharmaceutical and Neutraceutical therapies in every day practice. RECENT NEWSMedisafe 1 Technologies Receives an Unsolicited Buyout at $0.33 Per Share
Press Release Source: Medisafe 1 Technologies Corp. On Monday March 21, 2011, 8:20 am EDT JERUSALEM, March 21, 2011 /PRNewswire-FirstCall/ -- Medisafe 1 Technologies Corp. (OTCBB:MFTH.ob - News), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company has received an unsolicited buy-out of all the outstanding shares of the Company at $0.33 per share subject to final due diligence of the Companys technology and other regulatory issues by a European based Investment House. Medisafe 1's management team and the Buying entity are currently conducting due diligence and should be able to provide to its shareholders further details in the coming weeks.
About Medisafe 1 Technologies Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.
Forward-Looking Statements This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov.
Media Contact: Jacob Elhadad CEO +972-524440000 Jacob.elhadad10@gmail.com Medisafe 1 Technologies to Sign Agreement for $5 Million Funding Commitment
Press Release Source: Medisafe 1 Technologies Corp. On Monday April 11, 2011, 11:32 am EDT
Company has Successfully Passed Due Diligence Stage. Letter of Intent Recently Signed With Investor Managed by Roswell Capital Partners. Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company intends to sign a final agreement to receive a $5,000,000 equity investment. Closing documents will be initiated within the next three to four days. Medisafe 1 Technologies recently signed a Letter of Intent to secure a $5,000,000 Equity Funding Facility with Centurion Private Equity, LLC ("Centurion"), an institutional investor managed by Roswell Capital Partners, LLC. Medisafe 1 Technologies has successfully passed the requisite stage of due diligence by Centurion. Medisafe 1 Technologies intends to use the funding facility to fund ongoing research and development, and to support general corporate purposes. Upon closing of the agreement, Centurion will be committed to purchase for cash consideration, subject to certain conditions and limitations described in the agreement, up to an aggregate of $5,000,000 of Medisafe 1 Technologies' common stock. Under the Equity Funding Facility, Medisafe 1 Technologies may, at its discretion, periodically sell to Centurion shares of Medisafe 1 Technologies' common stock at a price based upon the market price (as defined in the agreement) of Medisafe 1 Technologies' common stock. "Through this infusion of funding, Medisafe 1 Technologies will be able to advance rapid efforts to commercialize our life saving devices that prevent the incorrect administration of medicines and transfusions," said Jacob Elhadad, CEO of Medisafe 1 Technologies Corp. "Additional capital will enable the ongoing development of worldwide business activities, and the initiation of pilot programs in hospitals and medical clinics across the world." Roswell Capital Partners, LLC is a fund management company focused on private equity investments in small-cap publicly traded securities. Since 1994, its members have served in the Private Equity Markets as the Principal or Investment Banker for over 125 public companies including several biotechnology companies such as Celgene, and Peregrine Pharmaceuticals About Medisafe 1 Technologies Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient. Forward-Looking Statements This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov.
CONTACT
Medisafe 1 Technologies Corp 216 Jaffa Street Tel: +972-2-5021322 E-mail: |
Disclaimers
Neither HotShot Stocks Corp nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Hot Shot Stocks Corp, licensed by HotShot Stocks from Information Providers, or gathered by HotShot Stocks from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.
NEITHER HOTSHOT STOCKS CORP NOR THE INFORMATION POVIDERS SHALL HAVE ANY LIABILITY, CONTINGENT OR OTHERWISE FOR THE ACCURACY, COMPLETENESS, TIMELINESS, OR CORRECT SEQUENCING OF THE INFORMATION OR FOR ANY DECISION MADE OR ACTION TAKEN BY YOU IN RELIANCE UPON THE INFORMATION OR "HOTSHOTSTOCKS.COM," OR FOR INTERRUPTION OF ANY DATA, INFORMATION, OR ANY OTHER ASPECT OF "HOTSHOTSTOCKS.COM." THE PAST PERFORMANCE OF A MUTUAL FUND, STOCK, OR INVESTMENT STRATEGY CANNOT GUARANTEE ITS FUTURE PERFORMANCE.
NEITHER HOTSHOT STOCKS CORP. NOR ITS INFORMATION PROVIDERS MAKE ANY REPRESENTATIONS ABOUT THE SUITABILITY OF THE INFORMATION, SOFTWARE, PRODUCTS, OR SERVICES CONTAINED IN "HOTSHOTSTOCKS.COM" ALL SUCH INFORMATION, SOFTWARE, PRODUCTS, AND SERVICES ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.
If you have received this email in error, or you wish to no longer be on the HotShot Stocks mailing list, please click here, type in the active email address and the word UNSUBSCRIBE.
Disclosures: http://www.hotshotstocks.com are not registered investment advisers or broker/dealers. http://www.hotshotstocks.com makes no recommendation that the purchase of securities of companies profiled in this Web site is suitable or advisable for any person or that an investment such securities will be profitable. Profiles is a special advertising section presented by HotShotStocks.com. All material listed within http://www.hotshotstocks.com, http://www.hotshotstocks.com/profiles.htm, http://www.hotshotstocks.com/profiles-details_MFTH.htm. ("Profiles") was based upon information supplied by the company or from other sources believed to be reliable. The information contained Profiles is not guaranteed by Profiles to be accurate and should not considered to be all-inclusive. The companies discussed on Profiles except for those companies that appear on the URL http://HotShotStocks.com have not approved the statements made herein. Any discussions and pages contain forward looking statements that involve risks and uncertainties. A company's actual results could differ materially from those described in any forward - looking statements or announcements discussed on Profiles. All material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Profiles is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst, or underwriter. Companies profiled at URL http://www.hotshotstocks.com are ineligiable for recommendations on URL http://www.hotshotstocks.com for 90 days following final disposition of any compenstation. "Fair Disclosure". We expect to be compensated $500.00 by a third party.
